Accession Number:



Defining Hepatocellular Carcinoma Subtypes and Treatment Responses in Patient-Derived Tumorgrafts

Corporate Author:

University of Texas Southwestern Medical Center Dallas United States

Report Date:



Hepatocellular carcinoma HCC is the 6th most common cancer and 3rd leading cause of cancer-related death worldwide. We know that HCC subtypes exist because clear clinical, radiographic, and histological differences between patients with HCC are observed. In this study we proposed to investigate distinct subtypes of HCC using a mouse-human chimeric Patient Derived Xenograft PDX approach. So far, we have performed a large effort to implant 102 tumors from human HCC patients from Texas. We have established the protocol and the results have taught us that engraftment using a variety of transplantation techniques will result in a 25-30 engraftment efficiency for early stage surgical tumors. We have established 6 new human HCC PDX models that will be highly relevant for therapeutic and biological studies. These represent North American HCCs, including some patients with intermediateadvanced stage HCC, which is a unique resource for the field.

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017



Distribution Statement:

Approved For Public Release;

File Size: